Scholarlink

Background <p>Periodic fluorodeoxyglucose (FDG) positron emission tomography (PET)-computed tomography (CT)/CT-based response examinations are the current standard for clinical assessment of lymphoma treatment response. In this prospective study, we applied a blood-based multi-omics test, SeekInClarity, to assess treatment response and to predict therapeutic outcomes in the major lymphoma subtypes.</p> Methods <p>We prospectively recruited 116 lymphoma patients from two clinical centers, and collected blood samples at pre-treatment (baseline) and after two treatment cycles (landmark) to calculate molecular tumor burden (MTB) score using SeekInClarity. The “molecular response” framework, developed based on the MTB dynamic changes between baseline and landmark, was used to predict prompt treatment efficacy across various first-line regimens.</p> Results <p>Higher MTB scores correlated with advanced tumor stages, with MTB+ ratios of 31.8%, 63.6%, 84.6%, and 91.2% for stage I, II, III, and IV respectively. At landmark, MTB+ patients (<i>n</i> = 41) exhibited significantly worse progression-free survival (PFS, HR 7.78, 95% CI 3.00–20.18, <i>P</i> &lt; 0.0001) and overall survival (OS, HR 4.14, 95% CI 1.03–16.59, <i>P</i> &lt; 0.05) compared to the MTB- patients (<i>n</i> = 75). Multivariable Cox regression analysis demonstrated that only molecular response and interim PET/CT were independent predictor of treatment outcome, outperforming the clinical biomarkers B2M and LDH. Among the 108 patients with interim PET/CT response, SeekInClarity further identified 24 (22.2%) patients as molecular non-responders. Of these, 8 (33.3%) patients experienced disease progression within 27.5 months, while only 10 (11.9%) patients among the remaining 84 molecular responders progressed within 31.7 months. This significant difference indicated that molecular non-responders have notably worse PFS than molecular responders (<i>P</i> &lt; 0.01), particularly in aggressive B-cell and NK/T-cell lymphomas. These findings underscore the added value of molecular profiling in refining risk stratification beyond imaging alone.</p> Conclusions <p>The SeekInClarity-based molecular response predicts prompt treatment efficacy and serves as a valuable complementary tool for identifying non-responders among interim PET/CT response patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early assessment of therapeutic efficacy in lymphoma patients via a blood-based multi-omics response monitoring test

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Xinhua Wang,
  • Zhiming Li,
  • Yu Chang,
  • Shiyong Li,
  • Wei Wu,
  • Fangyuan Chang,
  • Yinyin Chang,
  • Dandan Zhu,
  • Desheng Gong,
  • Mingzhi Zhang,
  • Mao Mao

摘要

Background

Periodic fluorodeoxyglucose (FDG) positron emission tomography (PET)-computed tomography (CT)/CT-based response examinations are the current standard for clinical assessment of lymphoma treatment response. In this prospective study, we applied a blood-based multi-omics test, SeekInClarity, to assess treatment response and to predict therapeutic outcomes in the major lymphoma subtypes.

Methods

We prospectively recruited 116 lymphoma patients from two clinical centers, and collected blood samples at pre-treatment (baseline) and after two treatment cycles (landmark) to calculate molecular tumor burden (MTB) score using SeekInClarity. The “molecular response” framework, developed based on the MTB dynamic changes between baseline and landmark, was used to predict prompt treatment efficacy across various first-line regimens.

Results

Higher MTB scores correlated with advanced tumor stages, with MTB+ ratios of 31.8%, 63.6%, 84.6%, and 91.2% for stage I, II, III, and IV respectively. At landmark, MTB+ patients (n = 41) exhibited significantly worse progression-free survival (PFS, HR 7.78, 95% CI 3.00–20.18, P < 0.0001) and overall survival (OS, HR 4.14, 95% CI 1.03–16.59, P < 0.05) compared to the MTB- patients (n = 75). Multivariable Cox regression analysis demonstrated that only molecular response and interim PET/CT were independent predictor of treatment outcome, outperforming the clinical biomarkers B2M and LDH. Among the 108 patients with interim PET/CT response, SeekInClarity further identified 24 (22.2%) patients as molecular non-responders. Of these, 8 (33.3%) patients experienced disease progression within 27.5 months, while only 10 (11.9%) patients among the remaining 84 molecular responders progressed within 31.7 months. This significant difference indicated that molecular non-responders have notably worse PFS than molecular responders (P < 0.01), particularly in aggressive B-cell and NK/T-cell lymphomas. These findings underscore the added value of molecular profiling in refining risk stratification beyond imaging alone.

Conclusions

The SeekInClarity-based molecular response predicts prompt treatment efficacy and serves as a valuable complementary tool for identifying non-responders among interim PET/CT response patients.